Conformationally restricted 5,6-bicyclic amidines act as potent arginine surrogates, significantly increasing the in vitro potency of platelet GPIIb-IIIa receptor antagonists.
Answers are grounded in this paper and cite their sources.
Bicyclic amidines may boost GPIIb-IIIa antagonist potency in vitro; leaves open clinical translation and in vivo validation.
The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.
No takes yet. Share an insight, caveat, or question.
Sall et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: